Share: Facebook Twitter LinkedIn
Activity Provided By:

ACHL

Answers to the Questions You May Not be Asking: Treating Ulcerative Colitis Considerate of Patient-Centric Factors

Access Activity

Overview / Abstract:

Are you aware of the latest evidence-based strategies in ulcerative colitis (UC)? Looking to expand your ability to incorporate patient-centric factors into selection of therapy for UC? Navigate through this novel, interactive self-directed activity designed to optimize your decision making in selection of therapy for UC. View expert perspectives and insights who can help you apply newer strategies such as treat-to-target (T2T) and therapeutic drug monitoring (TDM) for the treatment for your UC patients. Also included are downloadable decision aids to share with your patients and “how I do it” patient and clinician interactions to help guide conversations on goal setting and treatment selection. Don’t get left behind on the latest UC therapies and treatment strategies.

Expiration

Jul 21, 2024

Discipline(s)

Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME

Format

Online

Credits / Hours

1.0

Accreditation

ACCME

Presenters / Authors / Faculty

Millie Long, MD, MPH
Associate Professor
Department of Medicine, Division of Gastroenterology and Hepatology School of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC

Neilanjan Nandi, MD
Associate Professor of Clinical Medicine
Department of Medicine, Division of Gastroenterology & Hepatology
University of Pennsylvania
Philadelphia, PA

Sponsors / Supporters / Grant Providers

Provided by the Academy for Continued Healthcare Learning (ACHL).

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Keywords / Search Terms

ACHL CME, CE, Takeda, Neilanjan Nandi, Ulcerative Colitis, UC, Crohn’s Disease, Crohn’s, CD, IBD, QOL, treatment, goals, T2T, treat-to-target, diagnosis, Disease Monitoring, corticosteroid dependence, inflammatory bowel disease, quality of life, inflammatory bowel disease, vedolizumab, DMARD, biologic Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map